natgillin/translations-raw huggingface dataset:
In one embodiment, the multipurpose airway device is suitable for a child and has circular internal and external profiles, i.e. has a circular cross-section. In this embodiment, the internal diameter of the airway body is preferably in the range of from approximately 7 mm to approximately 40 mm, e.g. 11.75 mm. 
HR P20190149 T1 Višenamjenski uređaj za disanje sukladno bilo kojem prethodnom zahtjevu, pri čemu je višenamjenski uređaj za disanje prikladan za djecu, a cjevasto tijelo ima okrugli poprečni presjek; i eventualno pri čemu je unutarnji promjer cjevastog tijelo u rasponu između približno 7 i 40 mm, npr. 11,75 mm.
The exposition of LDL to globin-free haemin (the complex of ferric ion (Fe3+) with protoporphyrin IX), derived from the haemoglobin in circulating erythrocytes, serves as a physiological source of pro-oxidant Fe3+ capable to promoting LDL oxidation. 
Izlaganje LDL heminu bez globina (kompleks feri iona (Fe) s protoporfirinom IX), dobivenim iz hemoglobina u cirkulirajućim eritrocitima služi kao fiziološki izvor pro-oksidanta Fe"" koji može potaknuti LDL oksidaciju.
An instant coffee with coffee grounds and foam characterized by 65% to 97.5% on dry matter of roasted and ground coffee beans and 2.0% to 2.5% on dry matter of flavoring substance obtained by a production method comprising the steps of 
PATENTNI ZAHTJEVI Instant kava sa talogom i pjenom okarakterizirana sa 65% do 97.5% suhe tvari pečenih i mljevenih zrna kave i 2.0% do 2.5% suhe tvari supstance za poboljšanje ukusa dobijena proizvodnom metodom koja obuhvaća korake
A composition as defined in claim 1 or 2, comprising crystalline apixaban particles having a mean particle size equal to or less than about 85 µm, crystalline apixaban particles having a D90 equal to or less than 85 µm, crystalline apixaban particles having a D90 equal to or less than 50 µm, crystalline apixaban particles having a D90 equal to or less than 30 µm, crystalline apixaban particles having a D90 equal to or less than 25 µm. 
Kompozicija kao stoje definirano u patentnom zahtjevu 1 ili 2, koja sadrži čestice kristalnog apiksabana koje imaju D90 manji od 85 µm, čestice kristalnog apiksabana koje imaju D90 manji od 50 µm, čestice kristalnog apiksabana koje imaju D90 manji od 30 µm, ili čestice kristalnog apiksabana koje imaju D90 manji od 25 µm mjereno pomoću rasipanja laserske svjetlosti.
An isolated antibody or antibody fragment according to one of the preceding claims wherein said antibody or fragment thereof is a monoclonal antibody. 
Izolirano antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 1 ili 2, naznačen time, što je navedeno antitijelo ili njegov fragment monoklonsko antitijelo.
The method of claim 1, wherein the mouse lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region. 
mišu nedostaje lokus varijabilne regije lakog lanca endogenog mišjeg imunoglobulina koji preuređenjem može tvoriti gen koji kodira varijabilnu regiju k miša;
This led to an increase in the fraction of non-fucosylated oligosaccharides attached to the Fc region of the antibodies, including bisected non-fucosylated oligosaccharides, as has been described in WO 2004/065540 (FIGS. 
Protutijelo prema zahtjevu 13, naznačeno time, da spomenuto protutijelo ima povećanje u frakciji prepolovljenih vrsta ne-fukoziliranih oligosaharida priključenih na navedeno Fc-područje koje je pod glikoinženjeringom.
acquiring a signal (90 u) proportional to the actual leakage currents and disconnecting the load (16) from the electrical network (10) when reaching a dangerous condition corresponding to an acquired signal (90 u) of a magnitude greater than a limit value. 
(iv) dobivanjem proporcionalnog signala (90u) koji je proporcionalan pravoj parazitnoj struji i odspajanjem trošila (16) s električne mreže (10) kada se postiže opasno stanje koje odgovara dobivenom signalu većem od granične vrijednosti. 2.
The different salts of the compound may exist in the form of solvates, i.e. in the form of hydrates and all these forms are also within the scope of the present invention. 
Kvorin), po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
The compound of claim 1, wherein R2 and R3 combine with the carbon to which they are attached to form optionally substituted azetidinyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R* i R* kombiniraju s ugljikom na kojeg su vezani kako bi tvorili izborno supstituirani homopiperidinil.
an effective amount of borate, the effective amount being less than 0.5 w/v % of the overall composition; 
učinkovitu količinu borata, te je učinkovita količina borata najmanje 0,05 m/v% ali manja od 0,5 m/v% ukupnog pripravka;
A protein or protein molecule composition according to claim 29, wherein said antibody binds the TA- MUC1 epitope, comprising the amino acid sequence DTR, wherein the T is glycosylated. 
protutijelo u skladu s (a) koje se veže na epitop TA-MUC1, koji sadrži aminokiselinski slijed DTR, gdje je T glikoziliran; i/ili
Impurity analysis by HPLC, as described in European Pharmacopoeia, determined that pravastatin C was present in an amount of 0.04% by weight. 
Analiza onečišćenja HPLC-om, kako je opisano u Europskoj farmakopeji, utvrdila je prisutnost pravastatina C u količini od 0.04% ukupne težine.
The method for anchoring the waterproofing liner (13) according to claim 1, characterised in that each seaming band (14) consists of a plurality of modular anchor strips (14.1 - 14.n) axially aligned, seamed together and fastened to the concrete curbs (15, 23). 
Postupak za sidrenje vodonepropusnog vijenca (13) prema zahtjevu 1, naznačen time da se svaka šavno spojena traka (14) sastoji od mnoštva modularnih traka za sidrenje (14.1 - 14.n) koje su aksijalno poravnate, međusobno povezane 1 pričvršćene na betonske rubnike (15, 23).
The cake is then ground to a fine white powder. 
Kolač je zatim samljeven i fini bijeli prašak.
Method according to claim 1 or 2 further characterized in that said concentrator (C) determines the amount (L) of consumption related data also on the basis of parameters, especially a time interval, previously stored in said concentrator (C) from a centralized management facility (AMM). 
Metoda prema patentnom zahtjevu 1 ili 2 koja je nadalje naznačena time da navedeni sabirnik (C) određuje količinu (L) navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju i na temelju parametara, posebno vremenskog intervala, prethodno pohranjenih u navedenom sabirniku (C) iz središnje upravljačke jedinice (AMM).
The OWT heating unit consists of the surface high-frequency generator 10 and the OWT heating unit line, which is distributed along the entire length of OWT 5, heated by high-frequency currents, including the third cord 11 of the three-cord electrical cable 9 . 
Toplinska jedinica CNI-a se sastoji od površinskog generatora visoke frekvencije 10 1 linije zagrijavanja CNI-a koja se pruža duž cijele dužine CNI-a 5, zagrijavanog strujama visoke frekvencije, uključujući treću žicu 11 trožičnog kabla 9.
A process for making a composition as defined in Claim 2, which process comprises mixing the compound as defined in Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. 
Postupak za proizvodnju pripravka definiranog u patentnom zahtjevu 2, koji sadrži miješanje spoja kao što je definiran u patentnom zahtjevu 1, ili njegove farmaceutski prihvatljive soli, 1 farmaceutski prihvatljivog nosača ili razrjeđivača.
As group (6g), wherein bond a is a single bond; and Z is —C(═R32)—. 
Spoj prema zahtjevu 9, pri čemu je veza a jednostruka veza; a Z je ili -C(=R)-.
The device according to claim 1, wherein the body of permanent-magnetic material is a polymer-bonded composite which comprises a macromolecular polymer and a permanent-magnetic powder, said permanent-magnetic powder being selected from the group of magnetic materials consisting of cobalt, iron, and their alloys, chromium dioxide, magnetic oxide spinels, magnetic garnets, magnetic ferrites including magnetic hexaferrites, alnico alloys, samarium-cobalt alloys, and rare-earth-iron-boron alloys. 
Uređaj sukladno patentnom zahtjevu 1, naznačen time, da je tijelo od permanentno magnetskog materijala izrađeno od kompozitnog materijala vezanog polimerom koje uključuje makromolekularni polimer i prašak permanentno magnetskog materijala, pri čemu je magnetski prašak odabran iz skupine koju čine magnetski materijali u koje spadaju kobalt, željezo i njihove legure, krom dioksid, magnetski oksid spineli, magnetski granati, magnetski feriti uključujući magnetske heksaferite, alnico legure, legure samarij-kobalta i legure rijetka zemlja-Željezo-bor.
is a substituent selected from the group consisting of i) hydrogen, ii) methyl, iii) ethyl, iv) hydroxymethyl, v) hydroxyethyl, vi) phenyl optionally substituted with 1 to 3 fluoro groups, vii) benzyl optionally substituted with 1 to 3 fluoro groups, and viii) pyridyl; 
je supstituent kojeg se bira iz skupine koju čine i) vodik, ii) metil, iii) etil, iv) hidroksimetil, v) hidroksietil, vi) fenil, izborno supstituiran s 1 do 3 fluorne skupine, vii) benzil, izborno supstituiran s 1 do 3 fluorne skupine, te viii) piridil;
less than or equal to 10000 litres, less than or equal to 5000 litres, or less than or equal to 2500 litres. 
manji od ili jednak 10000 l, manji od ili jednak 5000 l, ili manji od ili jednak 2500 l.
or saline were administered (n=8 per group) and the EEG recording was continued for 60 min. 
ili fiziološke otopine (n = 8 po skupini) i bilježenje EEG-a je nastavljeno tijekom 60 minuta.
In another presently preferred construction and arrangement, the components of the invert arm assembly are contained within a modular unit so that by simply providing power to the electric motors, and any needed or desired cooling or lubricating fluids to the unit, the entire unit is operational. 
U još jednom mogućem preferiranom krostrukcijskom i izvedbenom rješenju, elementi sklopa invertirajuće ruke su smješteni unutar modularne jedinice, tako da je uz napajanje elektromotora i eventualno dodavanje sredstava za hlađenje ili podmazivanje jedinice, cijeli sustav operabilan.
is present and is conjugated to a lipophilic substituent. 
(b) X30 je prisutan i konjugiran na lipofilni supstituent.
In certain embodiments, when the RH is increased from about 0% to about 95% RH, Form C exhibits a mass change of less than about 1%, less than about 0.5%, or less than about 0.2%, e.g., about 0.17%, of the starting mass of the sample. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što ima grafički prikaz toplinske gravimetrijske analize koji sadrži gubitak mase manji od otprilike 0,5% prilikom grijanja od otprilike 25%C€ do otprilike 150*C.
The ophthalmic aqueous solution according to claim 1 wherein the PGF2a analogue is selected from the group consisting of latanoprost, isopropyl unoprostone, travoprost, bimatoprost and tafluprost or a mixture of two or more thereof. 
Oftalmološka vodena otopina prema patentnom zahtjevu 1, naznačena time da PGF2a je analog izabran iz skupine koja sadrži latanoprost, izopropil unoproston, travoprost, bimatoprost i tafluprost ili smjesu dva ili više njih.
The following morning a sample was taken for HPLC and the reaction was dried and the organic layer was concentrated on the rotovap. 
Sljedeće jutro je uzorak bio uzet za HPLC i reakcijska smjesa je bila osušena i organski sloj je bio koncentriran na rotacijskom uparivaču.
wherein the isolated S2 component is provided to the estimator input port of the frequency estimator. The blood pressure analyzer according to claim 19, wherein the input port is further configured to receive an electrocardiogram (ECG) signal corresponding to the PCG signal, and 
Uređaj za analizu krvnog tlaka prema zahtjevu 12, naznačen time da je ulazni priključak nadalje podešen za primanje signala elektrokardiograma (EKG) koji odgovara signalu PCG, te pri čemu je uređaj za izdvajanje dijastoličkog signala podešen za izdvajanje dijastoličkog signala korištenjem odgovarajućeg EKG signala,
Alternatively, the dry powder may be contained as a reservoir in a dose dry powder inhalation device. 
Alternativno, suhi prah može biti sadržan kao doza spremnika naprave sa suhim prahom za inhaliranje.
Use of a compound of formula (Compound I, trans -1-((1 R,3 S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine) or a salt thereof in the preparation of a medicament for the treatment of a disease selected from the group consisting of a disease involving psychotic symptoms, schizophrenia, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, and abuse disorders, e.g. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje bolesti izabrane iz skupine koja obuhvaća bolest koja uključuje psihotične simptome, anksiozne poremećaje, afektivne poremećaje uključujući depresiju, poremećaje spavanja, migrenu, neuroleptički inducirani parkinsonizam ili ovisnosti npr.
the heterocyclic group and the heteroaryl group may have substituents selected from the group consisting of a C1-5 alkyl group, -ORa, and -NRaRb; the alkyl group may be substituted by a hydroxyl group, a C1-5 alkoxy group, or an amino group; 
heterociklička skupina i heteroarilna skupina mogu imati supstituente, koje se bira iz skupine koju čine C1-5 alkilna skupina, -ORa i -NRaRb; alkilna skupina može biti supstituirana s hidroksilnom skupinom, C1-5 alkoksi skupinom ili amino skupinom;
The wellbore servicing apparatus according to claim 16, wherein the first mandrel is configured to move longitudinally along the central axis in response to a pressure. 
Uređaj (100) za servisiranje kanala bušotine sukladno Zahtjevu 1, naznačen time da je prvi mandrel (228) konfiguriran na način da se longitudinalno pomiče duž središnje osi (135) posljedično reagirajući na pritisak.
A solid oral extended release pharmaceutical dosage form comprising a extended release matrix formulation in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than 60 % of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than 20 % points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 6, gdje formulacija matrice s produljenim otpuštanjem nakon skladištenja na 25°C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, kada je mjerenje provedeno u USP aparatu 1 (košara) pri 100 okr/min u 900 ml simulirane želučane tekućine bez enzima (SGF) pri 37°C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 i 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
HUVEC were isolated and cultured in M199 and 20% FCS (Fetal Calf Serum). 
HUVEC su izolirane i uzgajane u M199 1 20% FCS (fetalni goveđi serum, Fetal Calf Serum).
The capsule according to claim 6, wherein the valve means is an integral part of the plate. 
Kapsula u skladu s patentnim zahtjevom 6, naznačena time što ventil (15) je sastavni dio ploče.
and R15 are independently hydrogen or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl. 
R14 i R15 su neovisno vodik ili izborno supstituirana skupina, koju se bira između nerazgranatog ili razgranatog (C;-Cg) alkila, (C3-Cg) cikloalkila, heterociklila, arila i heteroarila.
Wind system (1) according to claim 1, characterised in that said recovering system (8) is made of a trellis-type structure. 
Vjetreni sustav (1) prema zahtjevu 14, naznačen time da spomenuti prijenosni sustav uključuje:
A composition comprising a compound according to any one of the preceding claims, and an agriculturally acceptable formulation adjuvant. 
Pripravak naznačen time što sadrži spoja prema bilo kojem od prethodnih patentnih zahtjeva, te poljoprivredno prihvatljiv formulacijski dodatak
The process of claim 14, wherein after the ferric ion source has completely dissolved, the temperature of the solution is lowered to a range of from 15°C to 75°C. to present hydrolysis of pyrophosphate. 
Postupak prema zahtjevu 14, gdje nakon što se izvor feri iona potpuno otopi, temperatura otopine se smanjuje do raspona od do radi hidrolize pirofosfata.
30C): An isolated chimeric polypeptide encoding for H68654_1_P12 (SEQ ID NO:38), comprising a first amino acid sequence being at least 90% homologous to 
Farmaceutski pripravak naznačen time da sadrži barem jedan CIORF32 polipeptid ektodomene odabran iz skupine koja sadrži: i. -C10RF32 polipeptid ektodomene koji sadrži sekvencu amino kiseline iz SEQ ID NO: 299; ii.
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. 
KOH ili njegov solvat, oksid, ili njegova farmaceutski prihvatljiva sol.
The dosage form of claim wherein the content of rasagiline in the core is 0.5 mg and the core comprises 45.5 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, and the acid resistant coating of the dosage form comprises two coating layers, of which the inner of the two coating layers comprises 3.5 mg of hypromellose and the outer of the two coating layers comprises 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine. 
Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je jezgra u obliku tablete, kod čega je sadržaj rasagilina 1,0 mg, a tableta sadrži 45,0 mg manitola, 0,4 mg aerosila, 5,0 mg škroba NF, 20,0 mg prethodno želatiniranog škroba, 1,5 mg stearinske kiseline, 1,5 mg talka, 3,5 mg hipromeloze, 4,0 mg kopolimera metakrilna kiselina - etil akrilat, 0,8 mg trietil citrata, 1,9 mg ekstra finog talka i 2,0 mg agensa za boju obloge.
The communication method according to claim 7, wherein each of the mapping candidates of the first search space and each of the mapping candidates of the second search space is an Enhanced Physical Downlink Control Channel (EPDCCH) candidate in the data region. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 ili 8, naznačen time što je kandidat mapiranja kandidat Poboljšanog Fizičkog Kontrolnog Kanala Silazne Veze, EPDCCH, u području podataka i sastoji se od CCE-ova istog broja kao i vrijednost razine agregacije.
enzymatic hydrolysis of the lignocellulosic material to obtain enzymatically hydrolysed lignocellulosic material, 
predobrade lignoceluloznog materijala radi dobivanja prethodno obrađenog lignoceluloznog materijala,
A manipulating inspection device according to claim 4 or 5, characterized in that the tilting part of the supporting leg (1.2) is pivotally connected to its fixed part, whereas this rotary connection is adapted for locking the tilting part in the working and transport position. 
Manipulacijski inspekcijski uređaj u skladu s patentnim zahtjevom 4 ili 5, naznačen time što je nagibajući dio nosive noge (1.2) zakretljivo povezan s odgovarajućim fiksnim dijelom, gdje je to zakretljivo povezivanje prilagođeno za zabravljivanje nagibnog dijela u radni i transportni položaj.
2 and 3 show detailed diagrams of parts of the FIG. 
prikazuju detaljne dijagrame dijelova naprave sa Slike 1.
SUMMARY OF INVENTION The invention provides for an oligomeric compound comprising three regions: 
Oligomerni spoj dug od 8 do 35, naznačen time da obuhvaća tri regije:
The superhydrophobic coating of claim 1, wherein the resin is hydrophobic. 
Super hidrofobni premaz u skladu s patentnim zahtjevom 1, naznačen time, da je smola hidrofobna.
A compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein R5 is (R) 2-hydroxy-1-methylethyl. 
Spoj u skladu s patentnim zahtjevom 18, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R5 je (R) 2-hidroksi-1 -metiletil.
[1′] A compound represented by the following formula (I′): 
PATENTNI ZAHTJEVI Sastav predstavljen slijedećom Formulom (1): pri čemu:
An anti-LAG-3 antibody and an anti-PD-1 antibody for use in treating a solid tumor in a human patient, wherein the treatment comprises at least one administration cycle, wherein the cycle is a period of eight weeks, wherein for each of the at least one cycles, four doses of the anti-LAG-3 antibody are administered at a dose of 3, 20, 80, or 240 mg and four doses of the anti-PD-1 antibody are administered at a dose of 80 or 240 mg; 
Anti-LAG-3 antitijelo za primjenu u liječenju solidnog tumora kod humanog pacijenta, gdje liječenje obuhvaća najmanje jedan ciklus administracije, gdje ciklus je period od osam tjedana, gdje za svaki od najmanje jednog ciklusa, četiri doze anti-LAG-3 antitijela su administrirane u dozi od 3, 20, 80, ii 240 mg i četiri doze anti-PD-1 antitijela su administrirane u dozi od 80 ili 240 mg; anti-LAG-3 antitijelo sadrži varijabilne regije teškog i lakog lanca koje sadrže sekvence prikazane u SEK ID BRojevima:3 i 5, redom; i anti-PD-1 antitijelo sadrži
In another embodiment during step A) the aligning edge of the first coupling part of the first floor panel is positioned at a distance from the second coupling part of the second floor panel, which will facilitate coupling of the floor panels, and which will prevent scraping of (the upper surface of) the floor panels against each other, which could undesirably damage the floor panels. 
Postupak prema zahtjevu 28 ili 29, gdje je u koraku A) poravnati rub (41b) prvog spojnog dijela (22, 39, 51, 61) prvog podnog panela (24, 37, 41, 52, 70, 88, 97, 106, 114) smješten na udaljenosti od drugog spojnog dijela (23,
R1c and R1d are each independently selected from H and an optionally substituted alkyl, or together with the nitrogen to which they are attached form an optionally substituted heterocycloalkyl, wherein said optional substituents are one to three R10 groups; 
R"i R" su svaki nezavisno odabrani od H i proizvoljno supstituiranog C;-Cg alkila, ili zajedno s atomom dušika za kojega su vezani tvore proizvoljno supstituirani hetero Ca-C,g cikloalkil, pri čemu su navedeni nezavisni supstituenti jedna do tri R" skupine;
The container bears multiple doses that are isolated individually from the bulk of powder by volumetric displacement. 
Unutar spremnika nalazi se veći broj doza koje su principom volumetrijskog doziranja pojedinačno izolirane od spremišta praška.
treating the salt of isomer IIIb obtained in step (b) to form isomer IIIb. 
(c) obradom soli izomera IIIb, dobivene u koraku (b), kako bi se dobilo izomer IIIb.
The composition for use according to claim 6 or the compound for use according to any of claims 7-10, wherein the cancer is non-small cell lung cancer, ovarian cancer, breast cancer, cervical cancer, pancreatic cancer, prostate cancer, stomach cancer, brain cancer, liver cancer, metastatic cancer, or testicular cancer. 
Inhibitor tirozin hidroksilaze, promotorski spoj za melanin, promotorski spoj za p450 3A4 ili inhibitor leucin aminopeptidaze za uporabu prema bilo kojem od patentnih zahtjeva 2-5, naznačen time što je rak odabran od raka dojke, raka pluća ne malih stanica, raka jajnika, raka grlića maternice, raka gušterače, raka želuca, raka mozga, Traka jetre, raka testisa, leukemije ili limfoma.